Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDOV-Immune in Advanced Solid Tumors
NCT06910657Phase 1Recruiting
- Sponsor
- ViroMissile
- Start
- Aug 2025
- Primary completion
- Jan 2027
- Modality
- Oncolytic Viruses
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of IDOV-Immune in solid tumor, sponsored by ViroMissile. Primary endpoints: Incidence of Dose-Limiting Toxicities at 28 days, Safety and Tolerability of IDOV-Immune by Dose Level at 90 days and 2 more. Started Aug 2025; status: recruiting.
02
Drugs
IDOV-Immune
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06910657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06910657.